[Home] [Reports] [Startups] [ONLINE STORE] [site map]

A Worldwide Business Report
from MedMarket Diligence
:

 

 

Products, Technologies and Markets Worldwide
for the Clinical Management of Obesity, 2011-2019

 

A worldwide report on the products, technologies and markets in the treatment of obesity.

· 308 pages   · 79 Exhibits  · 47 Company Profiles     · February 2011     · Report #S835

Price: $2,950 (print or PDF; add $200 for both).
Site/Global License also available.

Order online or via order form.

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report addresses the challenges to obesity drug approval and the realistic prospects for obesity drugs and their changing opportunities to succeed in the U.S. and international markets. The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Methodology

Download the report now
by purchasing direct from us online,


Via Google Wallet (below)

Or fax/email us
your
order form
 

Single user
price $2,950

Table of Contents

executive summary

Section 1: CLINICAL BACKGROUND of obesity

1.1 Clinical Diagnosis of Obesity

1.1.1 Body Mass Index Scale

1.1.2 Measuring BMI vs. Measuring Adiposity

1.1.3 Classification of Obesity

1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity

1.1.5 Genetic Testing for Obesity

1.2 Obesogenic Influences

1.2.1 Dietary Changes Over the Last Twenty Years

1.2.2 Sedentary Lifestyles

1.2.3 Ongoing Research into Causes

1.3 Metabolic Pathways of Energy Homeostasis

1.3.1 Role of the Hypothalamus

1.3.2 Role of the Stomach

1.3.3 Role of the Small Intestine

1.3.4 Role of the Pancreas

1.3.5 Role of Adipose Tissue, An Endocrine Organ

1.3.6 Other Peptides

1.3.7 Obesity as Survival Mechanism

1.4 Co-Morbidities of Overweight and Obesity

1.4.1 Metabolic Syndrome

1.4.2 Effects of Obesity on Immune Function

1.4.3 Racial Differences in Co-morbidities

1.4.4 Type 2 Diabetes and Insulin Resistance

1.4.5 Hypertension

1.4.6 Dyslipidemia

1.4.7 Depression

1.4.8 Osteoarthritis

1.4.9 Asthma

1.4.10 Sleep apnea

1.4.11 Obesity and Cancer

1.5 Global Incidence and Prevalence of Obesity

1.5.1 By Geographic Region

1.5.1.1 USA, Canada, Mexico, Brazil

1.5.1.2 European Union

1.5.1.3 Asia-Pacific

1.5.2 By Age Group

1.5.2.1 Incidence and Prevalence among Children

1.5.2.2 Incidence and Prevalence among Elderly

1.5.3 Incidence and Prevalence of Morbid Obesity

 

SECTION 2:    THE IMPACT OF OBESITY

2.1    Costs Related to Treating Obesity and Co-Morbidities

2.1.1    Current Healthcare Expenses

2.1.1.1    Spending in the USA

2.1.1.2    Outside of the U.S., Spending Also Rising

2.1.2    The Looming Wave of Type 2 Diabetes

2.2    Impact on Businesses

2.2.1    Increased Health and Life Insurance Costs

2.2.2    Increased Costs Shouldered by Employers

2.2.3    Debate: Pay Employees to Lose Weight?

2.3    Legislating Prevention and Weight Loss

2.3.1    Healthcare Reform and Obesity

2.3.2    Changing Society

2.3.3    Pressure on the Food Industry

 

SECTION 3:    CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY

3.1    Role of Behavior Modification and Lifestyle Changes

3.1.1    Behavior Modification with Pharmacotherapies

3.1.2    Specialists’ Use of Pharmaceuticals

3.1.3    Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)

3.1.4    Why Diets Usually Fail

3.1.5    The Diogenes Study’s Dietary Recommendations

3.2    Non Prescription Weight Loss Products

3.3    Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs

3.3.1    The US FDA’s Guidance for Industry Developing Products for Weight Management

3.3.2    Definition of Satiety vs. Appetite Suppression

3.3.3    Definition of Combination Drugs

3.3.4    The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why

3.3.4.1    Phentermine/Fenfluramine Combination

3.3.4.2    Abbott’s Meridia (Sibutramine)

3.3.4.3    Vivus’ Qnexa: Out for Good?

3.3.4.4    Arena’s Lorqess: Not out of the picture yet

3.3.5    Prescription Drugs Currently on the Market

3.3.5.1    Appetite Suppression Drugs

3.3.5.2    Malabsorption Drugs

3.3.5.3    Satiety Drugs

3.3.5.4    Combination Drugs

3.3.6    Areas of Pharmaceutical Research

3.3.6.1    Melanocortin Receptor System

3.3.6.2    Cannabinoid Receptor Antagonists

3.3.6.3    GLP-1 Analogs

3.3.6.4    Methionine Aminopeptidase 2 (MetAP2) Inhibitor

3.3.6.5    Appetite Suppression Drugs

3.3.6.6    Malabsorption Drugs

3.3.6.7    Satiety Drugs

3.3.6.8    Combination Drugs

3.3.7    Safety: The Major Diet Drug Hurdle

3.4    Non- Pharmaceutical Options for Treating Obesity

3.4.1    Metabolic/Bariatric Surgery

3.4.1.1    Buchwald and Oien Research, 2009

3.4.1.2    Vertical Banded Gastroplasty

3.4.1.3    Roux-en-Y Surgery

3.4.1.4    Sleeve Gastrectomy

3.4.1.5    Biliopancreatic Diversion with Duodenal Switch

3.4.1.6    Jejuno-ileal Bypass: An Obsolete Procedure

3.4.2    Devices to Treat Obesity

3.4.2.1    Restrictive Devices

3.4.2.2    Artificial Fullness Devices

3.4.2.3    Malabsorption Devices

3.4.2.4    Devices to Control Gastric Emptying

3.4.2.5    Appetite Suppressive Devices

3.4.2.6    Gastric Electrical Stimulation

 

SECTION 4:    MARKET ASSESSMENT

4.1    Recent Developments Impacting Market Forecasts

4.2    Anticipated Developments Underlying the Market Forecast

4.3    Global Market for Obesity Treatments

4.3.1    Pharmaceuticals

4.3.1.1   Pharmaceutical Treatments for Obesity Entering the Market During the Forecast Period (2011-2019)

4.3.2    Devices

4.3.2.1   Medical Device Treatments for Obesity Entering the Market During the Forecast Period (2011-2019)

4.4    Market Shares of Leading Companies

4.4.1    Leading Pharmaceutical Companies

4.4.2    Leading Device Companies

4.5    Americas Market for the Treatment of Obesity

4.5.1    USA

4.5.2    Canada

4.5.3    Mexico

4.5.4    Brazil

4.6    European Market for the Treatment of Obesity

4.6.1    United Kingdom

4.6.2    Germany

4.6.3    France

4.6.4    Spain

4.6.5    Italy

4.6.6    Rest of Europe

4.7    Asia-Pacific Markets for the Treatment of Obesity

4.7.1    Japan

4.7.2    China

4.7.3    India

4.7.4    Australia

4.8    ROW Markets for the Treatment of Obesity

4.9    Strategies in the Global Obesity Market

4.9.1    Market Drivers

4.9.1.1    Significant Unmet Needs

4.9.1.2    The Need for a Variety of Treatment Options

4.9.1.3    Device Opportunity Grows Due to Lack of Drugs

4.9.1.4    Healthcare Reform

4.9.1.5    Treating Obesity to Avoid Costly Co-Morbidities

4.9.2    Market Restraints

4.9.2.1    Intense Complexity of the Metabolic Regulatory System

4.9.2.2    Time, Costs, Risks Involved in Developing a More Efficacious Drug

4.9.2.3    Tightening of Safety Requirements for Obesity Drugs

4.9.2.4    Data Showing Lack of Sustainable Weight Loss with Gastric Banding

4.9.2.5    Lack of Reimbursement

4.9.3    Strategies for Market Success

 

SECTION 5:    COMPANY PROFILES

5.1    7TM Pharma

5.2    Abbott Laboratories

5.3    Allergan

5.4    Amylin Pharmaceuticals

5.5    Arena Pharmaceuticals

5.6    AstraZeneca

5.7    BAROnova Therapeutics

5.8    BaroSense

5.9    BFKW, LLC (c/o Legacy Capital Advisors, LLC)

5.10    Covidien

5.11    CR Bard, Inc.

5.12    Crospon, Inc.

5.13    Eli Lilly & Company

5.14    EndoGastric Solutions

5.15    EndoSphere

5.16    EnteroMedics, Inc.

5.17    Ethicon Endo-Surgery, Inc. (JNJ)

5.18    Gelesis, Inc.

5.19    GI Dynamics

5.20    GlaxoSmithKline

5.21    Helioscopie

5.22    Interleukin Genetics

5.23    IntraPace

5.24    Laboratoire Endalis

5.25    Longevity Surgical, Inc.

5.26    Merck

5.27    MetaCure

5.28    Nestlé Healthcare Nutrition

5.29    NeuroSearch A/S

5.30    Novo Nordisk

5.31    Orexigen Therapeutics, Inc.

5.32    Pfizer, Inc.

5.33    ReShape Medical

5.34    Rhythm Pharmaceuticals

5.35    SafeStitch Medical, Inc.

5.36    Sanofi-Aventis

5.37    Satiety, Inc.

5.38    Scientific Intake, LLC

5.39    Shionogi & Co., Ltd.

5.40    Silhouette Medical, Inc.

5.41    Spatz FGIA, Inc.

5.42    Surface Logix, Inc.

5.43    USGI Medical

5.44    ValenTx, Inc.

5.45    Verva Pharmaceuticals Ltd.

5.46    Vivus, Inc.

5.47    Zafgen, Inc.

 

SECTION 6:    CLINICAL TRIALS

 

APPENDIX:  COMPANY DIRECTORY

 

List of Exhibits

 

Exhibit ES-1: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010

Exhibit ES-2: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries

Exhibit ES-3: Global Market for Treatment of Obesity, 2009-2019 (USD millions)

Exhibit ES-4: Regional Percent Revenue Shares, 2009

Exhibit ES-5: Manufacturer Percent Revenue Shares, Global Obesity Market, 2009

 

Exhibit 1-1: Calculation of Body Mass Index (BMI)

Exhibit 1-2: Proposed WHO Classification of BMI in Adult Asians

Exhibit 1-3: The International BMI Classification of Adult Underweight, Overweight and Obesity According to the World Health Organization (WHO)

Exhibit 1-4: The Human Gastrointestinal Tract

Exhibit 1-5: From Chronic Energy Imbalance to Co-Morbidities

Exhibit 1-6: Relative Risk of Mortality by BMI in US Men

Exhibit 1-7: Relative Risk of Mortality by BMI in US Women

Exhibit 1-8: World Incidence and Prevalence for Cancers Associated with Obesity

Exhibit 1-9: AICR Estimated Cases Per Year of Cancers Linked to Excss Body Fat

Exhibit 1-10: Populations and Rates of Obesity of Selected Countries, 2009

Exhibit 1-11: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010

Exhibit 1-12: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries

Exhibit 1-13: Percent of Adults Who are Overweight/Obese, by Country, 2010

Exhibit 1-14: USA Obesity Prevalence by State, 2004.

Exhibit 1-15: USA Obesity Prevalence by State, 2009.

Exhibit 1-16: Prevalence of Obesity in Canada for 1978-2005 (Measured Values)

Exhibit 1-17: Prevalence of Overweight and Obesity in Women and Men in Mexico from a Nationally Representative Sample and a Sample of Low-Income Rural Mexicans

Exhibit 1-18: WHO Prevalence of Obesity by Sex, Adults Aged 15 and Over, Latest Available Year, Europe

Exhibit 1-19: States of India ranked by percentage of overweight or obese (2006)

Exhibit 1-20: Percent of Children in Select Age Groups and Countries Who are Overweight (Including Obese), 2010

 

Exhibit 3-1: FDA List of Tainted Weight Loss Products, March 2009

Exhibit 3-2: Companies with Obesity Pharmaceuticals on Market or in Development, 2010

Exhibit 3-3: Number Of Bariatric Surgeons and Bariatric Surgery Operations, 2008

Exhibit 3-4: Global Trend in Metabolic/Bariatric Surgery, 2003-2013

Exhibit 3-5: Global Trends in Metabolic/Bariatric Surgery, 2003-2013

Exhibit 3-6: Regional Trend in Metabolic/Bariatric Surgery, USA/Canada, 2003-2008

Exhibit 3-7: USA/Canada Trends in Metabolic/Bariatric Surgery, 2003-2013

Exhibit 3-8: Regional Trends in Metabolic/Bariatric Surgery, Europe, 2003-2013

Exhibit 3-9: European Trends in Metabolic/Bariatric Surgery, 2003-2013

Exhibit 3-10: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013

Exhibit 3-11: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013

Exhibit 3-12: Regional Trend in Metabolic/Bariatric Surgery, Rest of World, 2003-2013

Exhibit 3-13: Regional Trends in Metabolic/Bariatric Surgery, Rest of World, 2003-2013

Exhibit 3-14: Companies with Obesity Devices on Market or in Development, 2010

 

Exhibit 4-1: Global Market for Treatment of Obesity, 2009-2019 (USD millions)

Exhibit 4-2: Global Market for Treatment of Obesity, 2009-2019 (USD millions)

Exhibit 4-3: Total Modality Market Shares by Percent Revenues, 2009

Exhibit 4-4: Total Modality Market Shares by Percent Revenue, 2019

Exhibit 4-5: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-6: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-7: Global Market for Device Treatment of Obesity, 2009-2019, (USD Millions)

Exhibit 4-8: Global Market for Medical Device Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-9: Percent Revenue Shares, Global Obesity Market, 2009

Exhibit 4-10: Percent Revenue Shares, Global Anti-Obesity Drug Market, 2009

Exhibit 4-11: Percent Revenue Shares, Global (Off-Label) Satiety Drug Market, 2009

Exhibit 4-12: Percent Revenue Shares, Global Pharmaceutical Appetite Suppression Market, 2009

Exhibit 4-13: Percent Revenue Shares, Global Anti-Obesity Devices Market, 2009

Exhibit 4-14: Percent Revenue Shares, Global Restrictive Devices Market, 2009

Exhibit 4-15: Percent Revenue Shares, Global Artificial Fullness Devices Market, 2009

Exhibit 4-16: Percent Revenue Shares, Global Appetite Suppression Devices Market, 2009

Exhibit 4-17: Americas Market for Treatment of Obesity, 2009-2019

Exhibit 4-18: Americas Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-19: USA Market for Treatments of Obesity, 2009-2019 (USD Millions)

Exhibit 4-20: Canada Market for Treatments of Obesity, 2009-2019 (USD Millions)

Exhibit 4-21: Mexico Market for Treatments of Obesity, 2009-2019 (USD Millions)

Exhibit 4-22: Brazil Market for Treatments of Obesity, 2009-2019 (USD Millions)

Exhibit 4-23: European Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-24: EU Obesity Percent Revenue Market Shares by Country, 2009

Exhibit 4-25: EU Obesity Percent Revenue Market Shares by Country, 2019

Exhibit 4-26: European Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-27: UK Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-28: Trends in Gastric Bypass vs. Gastric Banding, England, 2000-2007

Exhibit 4-29: Germany Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-30: France Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-31: Spain Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-32: Italy Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-33: Rest of Europe Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-34: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-35: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-36: Japan Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-37: China Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-38: India Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-39: Australia Market for Treatment of Obesity, 2009-2019 (USD Millions)

Exhibit 4-40: Rest of World Market for Treatment of Obesity, 2009-2019 (USD Millions)

 


Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.  Report #S835.  February 2011

 

Price:    $2,950 for print or PDF; add $200 to receive for both

 

Order for download online or fax us your order form.

Methodology.

MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

Or contact: Patrick Driscoll, (949) 891-1753 or patrick <at> mediligence <dot> com.

Refund Policy:
MedMarket Diligence print publications may be returned within 30 calendar days of purchase and must be in re-saleable condition for a refund to be issued. No refunds will be provided for digital products such as PDFs; customers are therefore advised to carefully evaluate information (website samples, descriptions, and information otherwise provided by MedMarket Diligence) on publications prior to purchase.

Copyright © 2011 MedMarket Diligence, LLC. All rights reserved.

 

 

Revised: 06/14/11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Our clients


Or call
+1.949.891.1753

About Us

 

Read
advanced medical technologies
blog


Medtech Startups

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports Coverage

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us